Drug Profile
BMS 181167-02
Alternative Names: BMS 18116702; D4APILatest Information Update: 16 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antivirals; Nucleosides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections; Sarcoma
Most Recent Events
- 12 Feb 2001 No-Development-Reported for HIV infections treatment in USA (Unknown route)
- 23 Oct 1997 No-Development-Reported for Sarcoma in USA (Unknown route)
- 14 Sep 1995 Preclinical development for Sarcoma in USA (Unknown route)